“$750 million nothing for big pharma to shell out”

They have shelled it out for access to promising preclinical technology just to have as a portfolio of shots on goal and we are not preclinical and notched an objective response in the safety and dose finding stage at initial dosage.

NEOG in just manufacturing process stage drew 200 upfront and 320 contingent.

Extreme risk here of course but actually less than while preclinical —with the initial results in and the reward potential literally enormous.

Ante$0.645 worth the gamble IMO.

Also there are many potential scenarios to attract big pharma capital short of an outright complete selloout in low single digits.

(The troika specifically trumpeted their expertise in this area as you know: Ahem)